Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-06-17
2011-11-15
Kosack, Joseph (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S293000, C514S409000, C514S411000, C514S424000, C514S462000, C514S468000, C514S473000, C546S082000, C546S083000, C548S410000, C549S265000
Reexamination Certificate
active
08058288
ABSTRACT:
The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
REFERENCES:
patent: 3097209 (1963-07-01), Jannsen et al.
patent: 3328156 (1967-06-01), Hopkins
patent: 3770748 (1973-11-01), Borck et al.
patent: 3933829 (1976-01-01), Archibald et al.
patent: 4001422 (1977-01-01), Danilewicz et al.
patent: 4013445 (1977-03-01), Bellus et al.
patent: 4076819 (1978-02-01), Maffrand
patent: 4145435 (1979-03-01), Szmuszkovicz
patent: 4439606 (1984-03-01), Du et al.
patent: 5442064 (1995-08-01), Pieper et al.
patent: 5614534 (1997-03-01), Binet et al.
patent: 5633247 (1997-05-01), Baldwin et al.
patent: 5668138 (1997-09-01), Baziard-Mouysset et al.
patent: 5852029 (1998-12-01), Fisher et al.
patent: 5981754 (1999-11-01), Badone et al.
patent: 6547958 (2003-04-01), Elomari
patent: 7074788 (2006-07-01), Kurz et al.
patent: 7122532 (2006-10-01), Walker et al.
patent: 7304081 (2007-12-01), Yao et al.
patent: 7776874 (2010-08-01), Yao et al.
patent: 2003/0203922 (2003-10-01), Patel et al.
patent: 2003/0229119 (2003-12-01), Kym et al.
patent: 2004/0188324 (2004-09-01), Elomari
patent: 2005/0020645 (2005-01-01), Ohta et al.
patent: 2005/0080078 (2005-04-01), Aquila et al.
patent: 2005/0282858 (2005-12-01), Yao et al.
patent: 2005/0288317 (2005-12-01), Yao et al.
patent: 2005/0288329 (2005-12-01), Yao et al.
patent: 2005/0288338 (2005-12-01), Yao et al.
patent: 2006/0004049 (2006-01-01), Yao et al.
patent: 2006/0009471 (2006-01-01), Yao et al.
patent: 2006/0009491 (2006-01-01), Yao et al.
patent: 2006/0116382 (2006-06-01), Yao et al.
patent: 2006/0122197 (2006-06-01), Yao et al.
patent: 2006/0122210 (2006-06-01), Yao et al.
patent: 2006/0149070 (2006-07-01), Rohde et al.
patent: 2006/0199816 (2006-09-01), Gillespie et al.
patent: 2007/0066584 (2007-03-01), Yao et al.
patent: 2007/0129345 (2007-06-01), Zhuo et al.
patent: 2007/0179142 (2007-08-01), Yao et al.
patent: 2007/0197506 (2007-08-01), Yao et al.
patent: 2007/0197530 (2007-08-01), Li et al.
patent: 2007/0208001 (2007-09-01), Zhuo et al.
patent: 2007/0213311 (2007-09-01), Li et al.
patent: 2007/0270424 (2007-11-01), Li et al.
patent: 2007/0293529 (2007-12-01), Li et al.
patent: 2008/0318991 (2008-12-01), Yao et al.
patent: 2009/0291946 (2009-11-01), Yao et al.
patent: 2009/0298808 (2009-12-01), Yao et al.
patent: 2004232939 (2004-11-01), None
patent: 2623567 (1976-12-01), None
patent: 0273659 (1988-07-01), None
patent: 2289498 (1976-05-01), None
patent: 57-156450 (1982-09-01), None
patent: 04-334357 (1992-11-01), None
patent: WO 00/01702 (2000-01-01), None
patent: WO0001704 (2000-04-01), None
patent: WO 00/59874 (2000-10-01), None
patent: WO 01/05790 (2001-01-01), None
patent: WO0100823 (2001-02-01), None
patent: WO 01/30780 (2001-05-01), None
patent: WO 02/06868 (2002-01-01), None
patent: WO 02/22572 (2002-03-01), None
patent: WO 02/069973 (2002-09-01), None
patent: WO03006364 (2003-01-01), None
patent: WO 03/010138 (2003-02-01), None
patent: WO 03/037271 (2003-05-01), None
patent: WO 03/037847 (2003-05-01), None
patent: WO 03/041641 (2003-05-01), None
patent: WO 03/045912 (2003-06-01), None
patent: WO 03/049736 (2003-06-01), None
patent: WO03049736 (2003-06-01), None
patent: WO 03/053915 (2003-07-01), None
patent: WO 03/099821 (2003-12-01), None
patent: WO 03/104207 (2003-12-01), None
patent: WO 2004/005295 (2004-01-01), None
patent: WO 2004/017961 (2004-03-01), None
patent: WO 2004/018479 (2004-03-01), None
patent: WO 2004/022554 (2004-03-01), None
patent: WO2004033427 (2004-04-01), None
patent: WO 2004/056745 (2004-07-01), None
patent: WO 2004/058727 (2004-07-01), None
patent: WO 2004/065351 (2004-08-01), None
patent: WO 2004/082687 (2004-09-01), None
patent: WO 2004/089470 (2004-10-01), None
patent: WO 2004/089896 (2004-10-01), None
patent: WO2004/094371 (2004-11-01), None
patent: WO 2004/096139 (2004-11-01), None
patent: WO2004094347 (2005-02-01), None
patent: WO 2005/037814 (2005-04-01), None
patent: WO 2005/047286 (2005-05-01), None
patent: WO 2005/060963 (2005-07-01), None
patent: WO 2005/061499 (2005-07-01), None
patent: WO 2005/108359 (2005-11-01), None
patent: WO 2005/110992 (2005-11-01), None
patent: WO 2006/002349 (2006-01-01), None
patent: WO 2006/002350 (2006-01-01), None
patent: WO 2006/002361 (2006-01-01), None
patent: WO 2006/012173 (2006-02-01), None
patent: WO 2006/012226 (2006-02-01), None
patent: WO 2006/012227 (2006-02-01), None
patent: WO 2006/020598 (2006-02-01), None
patent: WO 2006/047176 (2006-05-01), None
patent: WO 2006/053024 (2006-05-01), None
patent: WO 2006/055752 (2006-05-01), None
patent: WO 2007/038138 (2007-04-01), None
patent: WO 2007/067504 (2007-06-01), None
patent: WO 2007/084314 (2007-07-01), None
patent: WO 2007/089683 (2007-08-01), None
patent: WO 2007/101270 (2007-09-01), None
patent: WO 2007/103719 (2007-09-01), None
Alberts et al., “Selective Inhibition of 11β-Hydroxysteroid Dehydrogenease Type 1 Improves Hepatic Insulin Sensitivity in Hyperglycemic Mice Strains”,Endocrinology, (2003) 144: 4755-4762.
Albiston et al., “Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme”,Mol. Cell. Endocrin., (1994) 105: R11-R17.
Banker, G.S. ed. Modern Pharmaceutics, 3rded. Marcel Dekker, Inc., New York, 1996, pp. 451 and 596.
Barf et al., “Arylsulfonamidothiazoles as a New Class of Potential Antidiabetic Drugs. Discovery of Potent and Selective Inhibitors of the 11β-Hydroxysteroid Dehydrogenase Type 1”,J. Med. Chem., (2002) 45: 3813-3815.
Bellows et al., “Osteoprogenitor Cells in Cell Populations Derived From Mouse and Rat Calvaria Differ in Their Response to Corticosterone, Cortisol and Cortisone”,Bone, (1998) 23: 119-125.
Ben et al., “Synthesis of Optically Active α-Amino Esters via Dynamic Kinetic Resolution: A Mechanistic Study,”J. Org. Chem., 64: 7700-7706 (1999).
Berge et al., “Pharmaceutical Salts”,Journal of Pharmaceutical Science, 66, 2 (1977).
Bhargava et al., “The Serum- and Glucocorticoid-Induced Kinase Is a Physiological Mediator of Aldosterone Action”,Endocrinology, (2001) 142: 1587-1594.
Billaudel and Sutter, “Direct Effect of Corticosterone upon Insulin Secretion Studied by Three Different Techniques”,Horm. Metab. Res., (1979) 11: 555-560.
Blum et al., “Enzymology and Molecular Biology of Glucocorticoid Metabolism in Humans”,Prog. Nucl. Acid Res. Mol. Biol., (2003) 75:173-216.
Bolm C. et al.,J Org. Chem. 2005, 70, 2346.
Borthwick et al., “Design and Synthesis of Pyrrolidine-5.5′-trans-Lactams (5-Oxo-hexahydropyrrolo[3,2-b]pyrroles) as Novel Mechanism-Based Inhibitors of Human Cytomegalovirus Protease. 4. Antiviral Activity and Plasma Stability”,J. Med. Chem., (2003) 46, 4428.
Bujalska et al. “Does central obesity reflect ‘Cushing's disease of the omentum’?”,Lancet., (1997) 349: 1210-1213.
Burke et al., “α,α-Disubstituted Boron Enolates in the Asymmetric Synthesis of Quaternary Carbon Centers”,Organic Letters, 6/(3), pp. 405-407, 2004.
Buzas et al., “Synthèse et propriétés pharmacologiques de nouveaux dérivés de l'acide pyrrolidone-2-carboxylique-4”,Chimica Therapeutica, The European Journal of Medicinal Chemistry,7 (5), pp. 361-426, 1972 (translation provided).
Bursavich, M. G. And Rich, D. H., “Solid-Phase Synthesis of Aspartic Peptidase Inhibitors: 3-Alkoyx-4-Aryl Piperidines”,Org. Lett., (2001) 3, 2625.
Bydal et al., “Inhibition of type 2 17β-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationshps”,Steroids, (2004) 69, 325-342.
Canalis, E., ȁ
He Chunhong
Metcalf Brian W.
Qian Ding-Quan
Xu Meizhong
Yao Wenqing
Fish & Richardson P.C.
Incyte Corporation
Kosack Joseph
LandOfFree
Amido compounds and their use as pharmaceuticals does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amido compounds and their use as pharmaceuticals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amido compounds and their use as pharmaceuticals will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4280554